Skip to content

YELIVA – ABC294640 Trial

Discussion Board Forums Clinical Trials YELIVA – ABC294640 Trial

Tagged: 

Viewing 13 posts - 1 through 13 (of 13 total)
  • Author
    Posts
  • #99441
    bglass
    Moderator

    Hi Fred,

    Thank you for sharing this good news that your results so far show stability.  There is a lot of interest in our community about this and other new drugs on the horizon that bring us more and, hopefully, better treatment options.

    Fingers crossed that good results continue.

    Regards, Mary

     

    #99438
    fquail
    Participant

    Well, it’s still early, but decent results so far. I had my first “on trial” scan on December 2, and reviewed the results with Dr. Akce, my Emory oncologist and the PI for this trial at Emory, on December 5. The tumor had earlier been measured as 2.6 x 1.6 cm. In this scan it was reported at 2.8 x 1.8 cm, within the limits to conclude no progression and for me to remain on the trial. Dr. Akce also noted that it has been very difficult to precisely measure this tumor and there was a pretty good chance it really hasn’t grown at all. There has been no spread, and I have had really no side effects from the trial drug.

    I will have my next scan at the end of January.

    Fred

    #99437
    Litvak
    Participant

    Hi Fred,

    maybe the results regarding the effectiveness of YELIVA are in?

    – MB

     

    #99189
    bglass
    Moderator

    Hi Fred,

    Thank you for the update, and congratulations on starting this trial.  Fingers crossed the trial med brings you great results!

    Take care, regards, Mary

    #99187
    fquail
    Participant

    Well, I finally started on this trial a bit over two weeks ago. So far no real side effects to report. I won’t get much of an idea about the effectiveness until my next scan in late November. I’ll keep this thread updated.

    Fred

    #98863
    bglass
    Moderator

    Hi Fred,

    Thank you for your note.  I looked through the discussion board and while there is discussion about possibly seeking this treatment, I did not find any patients who wrote about being treated with Yeliva.  I also contacted a caregiver who was looking into it, and that patient did not in the end pursue Yeliva either.  Hopefully, if a patient or caregiver who is under Yeliva treatment sees this string, they will post on their experience.

    If you do enroll in this trial, I hope you will keep us posted.

    Regards, Mary

     

    #98857
    fquail
    Participant

    I may be going on this now Phase II trial. I’ll be meeting with Emory’s chief investigator on the trial within two weeks. Anyone have any more recent experience with this?  Thanks.

    Fred

    #91945
    mikeb
    Member

    Thanks Gavin – that’s all great info :)

    #91941
    gavin
    Moderator

    Hi Mike,

    Welcome to the site. Here is another page with some links on Yeliva for you. Hope that they are of use and interest to you and I look forward to hearing more from you.

    http://www.cholangiocarcinoma.org/punbb/viewtopic.php?id=14624

    Best wishes,

    Gavin

    #91944
    marions
    Moderator

    A bit more, Mike….. Angiogenesis plays a critical role in the growth and spread of cancer. A blood supply is necessary for tumors to grow beyond a few millimeters in size. Tumors can cause this blood supply to form by giving off chemical signals that stimulate angiogenesis. Tumors can also stimulate nearby normal cells to produce angiogenesis signaling molecules. The resulting new blood vessels “feed” growing tumors with oxygen and nutrients, allowing the cancer cells to invade nearby tissue, to move throughout the body, and to form new colonies of cancer cells, called metastases.

    Because tumors cannot grow beyond a certain size or spread without a blood supply, scientists are trying to find ways to block tumor angiogenesis. They are studying natural and synthetic angiogenesis inhibitors, also called antiangiogenic agents, with the idea that these molecules will prevent or slow the growth of cancer.

    Hugs
    Marion

    #91943
    mikeb
    Member

    Thanks so much Marion:

    Another article out yesterday. Was Mayo the Phase I? Interesting that it was ‘non-clinical’…

    http://tcbmag.com/News/Recent-News/2016/March/Mayo-Researchers-Make-Progress-In-Fight-Against-Ma

    I understood that it was an inhibitor – but some hope in the this statement

    “The Mayo researchers, along with Dr. Smith and others, concluded that Yeliva’s targeting of SK2 in the affected cells inhibited cancer proliferation and induced apoptosis – or self-destruction – in the cholangiocarcinoma cells.”

    :) thx! Mike B

    #91942
    marions
    Moderator

    mikeb…..hello and welcome to our group. I don’t think they set a date for a phase II study as of yet, but it will take some time i.e. months or more.
    As far as I understand it, SK2, is an angiogenesis inhibitor, which inhibits the growth of blood vessels. It does not necessarily kill tumors but instead may prevent tumors from growing. It is not a targeted agent and does not require molecular testing.
    Hugs,
    Marion

    #12295
    mikeb
    Member

    I recently saw this press release for YELIVA – ABC294640 – which is focused on Cholangiocarcinoma.

    http://www.thestreet.com/story/13490212/1/redhill-biopharma-announces-peer-reviewed-publication-demonstrating-therapeutic-potential-of-yeliva-in-cholangiocarcinoma-cancer.html

    Does anyone know if/when a Trial will take place?

    It looks like they have tried initial trial for Lymphoma. Does anyone know any feedback on this trial?

    It seems focused on Sphingosine kinase-2 (SK2) inhibitor. I’m not sure if this is important inhibitor in all Cholangiocarcinoma cases, or if only in sub-set with specific markers?

    Thanks to anyone with info :) mb

Viewing 13 posts - 1 through 13 (of 13 total)
  • You must be logged in to reply to this topic.
©2020 - All Rights Reserved, Cholangiocarcinoma Foundation
Scroll To Top